Efficacy of adalimumab therapy in experimental rat sclerosing encapsulated peritonitis model

Basit Öğe Kaydı
dc.authoridBakirdogen, Serkan/0000-0002-3448-0490
dc.contributor.authorAkgun, Yeliz
dc.contributor.authorBakirdogen, Serkan
dc.contributor.authorKocak, Meral Gulay Kadioglu
dc.contributor.authorBektas, Sibel
dc.contributor.authorDemir, Ceren
dc.contributor.authorAkbal, Erdem
dc.contributor.authorElmas, Sait
dc.date.accessioned2025-01-27T20:47:22Z
dc.date.available2025-01-27T20:47:22Z
dc.date.issued2019
dc.departmentÇanakkale Onsekiz Mart Üniversitesi
dc.description.abstractAim To investigate the efficacy of adalimumab treatment in an experimental rat sclerosing encapsulated peritonitis (SEP) model. Methods The study involved 40 Wistar albino rats divided into four groups: chlorhexidine (CH) group, control group, CH + adalimumab group, and CH + resting group. The control group received normal saline intraperitoneally (i.p.). Other groups received 0.1% CH gluconate, 15% ethanol, and normal saline mixture i.p. for three weeks in order to induce SEP. CH + adalimumab group received 5 mg/kg adalimumab i.p. at the beginning of week 4 and week 6, while CH + resting group was followed-up for three weeks without applying any procedure after the onset of SEP. Rats in groups CH and control group were sacrificed on day 21, and rats in group CH + adalimumab and CH + resting were sacrificed on day 42. All groups were evaluated for peritoneal thickness, inflammation, vascularization, and fibrosis. Results CH + adalimumab group showed a significant decrease in peritoneal thickness, fibrosis score, and vascular score compared with CH group and CH + resting group. Conclusion Adalimumab can prevent SEP development.
dc.description.sponsorshipCanakkale Onsekiz Mart University Scientific Research Projects Unit [TTU-2016-840]
dc.description.sponsorshipThe study was supported by Canakkale Onsekiz Mart University Scientific Research Projects Unit (TTU-2016-840).
dc.identifier.doi10.3325/cmj.2019.60.431
dc.identifier.endpage438
dc.identifier.issn0353-9504
dc.identifier.issn1332-8166
dc.identifier.issue5
dc.identifier.pmid31686457
dc.identifier.scopus2-s2.0-85074550282
dc.identifier.scopusqualityQ2
dc.identifier.startpage431
dc.identifier.urihttps://doi.org/10.3325/cmj.2019.60.431
dc.identifier.urihttps://hdl.handle.net/20.500.12428/24866
dc.identifier.volume60
dc.identifier.wosWOS:000506357400006
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherMedicinska Naklada
dc.relation.ispartofCroatian Medical Journal
dc.relation.publicationcategoryinfo:eu-repo/semantics/openAccess
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_WoS_20250125
dc.subjectNecrosis-Factor-Alpha
dc.subjectEndothelial Growth-Factor
dc.subjectRenin-Angiotensin System
dc.subjectMechanisms
dc.subjectExpression
dc.subjectInhibitors
dc.subjectFibrosis
dc.subjectMmp-3
dc.subjectBeta
dc.titleEfficacy of adalimumab therapy in experimental rat sclerosing encapsulated peritonitis model
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu